Agreement - October 12, 2021
CombiGene and Spark Therapeutics enter gene therapy agreement
CombiGene and Spark Therapeutics have announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, a gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark Therapeutics with the exclusive world-wide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the […]
Contract Services - August 18, 2020
Cobra Biologics completes production of master cell banks for CombiGene
Cobra Biologics and CombiGene have announced that Cobra has produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01. Critical to assuring ‘life time’ supply of therapeutic, this represents a further milestone in the future commercial manufacture of a drug candidate designed for the treatment of drug-resistant focal […]